WATERTOWN, Mass., April 23, 2024 — Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD. The Company has been selected for an invited talk, two oral presentations and two poster presentations.
Details of Tome’s ASGCT presentations are as follows:
Date: Thursday, May 9, 2024
Time: 12:00-7:00pm
Session: Poster Session: Gene Targeting and Gene Correction New Technologies
Abstract number: 1214
Title: L-PGI: a DNA Ligase Mediated Gene Editing System for Versatile and Precise Genomic Integration
Presenter: Jenny Xie
Other authors: A. Nan, C. Bartolome, S. Kumar, S. Halperin, M. Chickering, P. Grewal, L. Chavez and J.D. Finn
Date: Thursday, May 9, 2024
Time: 4:15-4:30pm
Session: Oral Abstract Session: Targeted Gene Insertion
Abstract number: 193
Title: Large Serine Integrase Off-Target Discovery and Validation for Therapeutic Human Genome Editing
Presenter: Dane Hazelbaker
Other authors: J.B. Mehta, D. Santesmasses, C. McGinnis, T. Biondi, A.M. Bara, X. Liang, B. Estes, J. Xie, K. Molugu, C. Luo, J. Cochrane, S. Kumar, M.H. Bakalar, J. Wang, D.J. O’Connell, J.D. Finn
Date: Thursday, May 9, 2024
Time: 4:45-5:00pm
Session: Oral Abstract Session: Targeted Gene Insertion
Abstract number: 195
Title: Programmable Genomic Integration in Induced Pluripotent Stem Cells and Hematopoietic Stem and Progenitor Cells
Presenters: Ravindra Amunugama and Minggang Fang
Other authors: K. Molugu, M.J. Kimaz, L. Herchenroder, A. Zieba, J. Wang, W. Wang, K. Zheng, J. Zhang, D. Harrison, S. Kumar, D. O’Connell, C. Luo and J.D. Finn
Date: Friday, May 10, 2024
Time: 8:00-8:26am
Session: Advances in Genome Editing: In Vivo Small Edits and the Promise of Large Insertions
Title: Integrase-Mediated Programmable Genomic Integration (I-PGI)
Presenter: Rahul Kakkar
Date: Friday, May 10, 2024
Time: 12:00-7:00pm
Session: Poster Session: Targeted Gene Insertion
Abstract number: 1676
Title: Low RT-Based Fidelity in Mouse Hepatocytes: Challenges and Solutions
Presenter: Maike Thamsen Dunyak
Other authors: P. Hanna, A. Nan, M. O’Hara, R. Pokharel, J. Xie and J.D. Finn
About Tome
Tome Biosciences, Inc., is a programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies. Follow us on X @Tome_Bio and on LinkedIn. www.tome.bio.
PGI™, I-PGI™ and L-PGI™ are brand names and technologies of Tome Biosciences, Inc.
Contacts:
For media:
CG Life
[email protected]
For investors:
Michelle Avery, PhD, SVP, Corporate Affairs
[email protected]
Read more: Veritas Strengthens Cyber Resilience with New AI-Powered Solutions